June 27, 2014
The Central Social Insurance Medical Council, a health ministry panel known as Chuikyo, will resume discussions on the impact that alleged exaggerated advertising of Novartis Pharma’s hypertension drug Diovan (valsartan) had on public healthcare finances, a ministry official said on...read more